Literature DB >> 15249723

Is there a role for chemosensitivity tests in head and neck cancer?

R Dollner1, C Granzow, J A Werner, A Dietz.   

Abstract

Despite many advances in predictive testing of human malignancies, we are far from using it routinely in clinical practice. Investigating the responsiveness of solid tumors to cytostatic drugs is particularly challenging. Nevertheless, for head and neck cancer, chemosensitivity testing is an increasingly attractive option, since chemotherapy has proven to have curative potential in the therapy of head and neck cancer, in particular in combination with radiation. The significant need for predictive methods to identify patients responsive to therapy, first of all in organ preservation programs, which is an alternative to first-line surgery, had recently renewed the discussion on a possible role of chemosensitivity testing in head and neck cancer. In this review, we discuss the current state of chemosensitivity testing in head and neck cancer. Recent methodological developments, in particular elimination of photochemical artifacts and inclusion of stromal cell response studies, may soon augment the value of ex vivo chemosensitivity testing for the management of head and neck cancer. Copyright 2004 S. Karger GmbH, Freiburg

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15249723     DOI: 10.1159/000077984

Source DB:  PubMed          Journal:  Onkologie        ISSN: 0378-584X


  3 in total

Review 1.  Response evaluation in head and neck oncology.

Authors:  Robert Mandic; Jochen A Werner
Journal:  Eur Arch Otorhinolaryngol       Date:  2010-04       Impact factor: 2.503

2.  Assay-based response evaluation in head and neck oncology: requirements for better decision making.

Authors:  Andreas Dietz; Andreas Boehm; Iris-Susanne Horn; Pierre Kruber; Ingo Bechmann; Wojciech Golusinski; Dietger Niederwieser; Ralph Dollner; Torsten W Remmerbach; Christian Wittekind; Stephan Dietzsch; Guido Hildebrandt; Gunnar Wichmann
Journal:  Eur Arch Otorhinolaryngol       Date:  2010-01-06       Impact factor: 2.503

3.  Establishment and characterization of novel human primary endometrial cancer cell line (ZJB-ENC1) and its genomic characteristic.

Authors:  Xiaozhen Liu; Zhuozhuo Ren; Yu Xu; Wei Sun; Yongfeng Li; Xinmiao Rui; Dafei Xie; Xuli Meng; Zhiguo Zheng
Journal:  J Cancer       Date:  2019-10-20       Impact factor: 4.207

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.